Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management.

IF 6.2 Q1 RESPIRATORY SYSTEM
Anolin Aslan, Cynthia Aslan, Naime Majidi Zolbanin, Reza Jafari
{"title":"Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management.","authors":"Anolin Aslan,&nbsp;Cynthia Aslan,&nbsp;Naime Majidi Zolbanin,&nbsp;Reza Jafari","doi":"10.1186/s41479-021-00092-9","DOIUrl":null,"url":null,"abstract":"<p><p>COVID-19 pandemic is a serious concern in the new era. Acute respiratory distress syndrome (ARDS), and lung failure are the main lung diseases in COVID-19 patients. Even though COVID-19 vaccinations are available now, there is still an urgent need to find potential treatments to ease the effects of COVID-19 on already sick patients. Multiple experimental drugs have been approved by the FDA with unknown efficacy and possible adverse effects. Probably the increasing number of studies worldwide examining the potential COVID-19 related therapies will help to identification of effective ARDS treatment. In this review article, we first provide a summary on immunopathology of ARDS next we will give an overview of management of patients with COVID-19 requiring intensive care unit (ICU), while focusing on the current treatment strategies being evaluated in the clinical trials in COVID-19-induced ARDS patients.</p>","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":"13 1","pages":"14"},"PeriodicalIF":6.2000,"publicationDate":"2021-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647516/pdf/","citationCount":"59","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pneumonia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41479-021-00092-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 59

Abstract

COVID-19 pandemic is a serious concern in the new era. Acute respiratory distress syndrome (ARDS), and lung failure are the main lung diseases in COVID-19 patients. Even though COVID-19 vaccinations are available now, there is still an urgent need to find potential treatments to ease the effects of COVID-19 on already sick patients. Multiple experimental drugs have been approved by the FDA with unknown efficacy and possible adverse effects. Probably the increasing number of studies worldwide examining the potential COVID-19 related therapies will help to identification of effective ARDS treatment. In this review article, we first provide a summary on immunopathology of ARDS next we will give an overview of management of patients with COVID-19 requiring intensive care unit (ICU), while focusing on the current treatment strategies being evaluated in the clinical trials in COVID-19-induced ARDS patients.

COVID-19急性呼吸窘迫综合征:可能的机制和治疗管理
新冠肺炎疫情是新时代的重大关切。急性呼吸窘迫综合征(ARDS)和肺功能衰竭是COVID-19患者的主要肺部疾病。尽管现在可以接种COVID-19疫苗,但仍迫切需要找到潜在的治疗方法,以减轻COVID-19对已经患病的患者的影响。FDA已经批准了多种实验性药物,但疗效和可能的副作用尚不清楚。可能世界范围内越来越多的研究检查潜在的COVID-19相关疗法将有助于确定有效的ARDS治疗方法。在这篇综述文章中,我们首先概述了ARDS的免疫病理,然后概述了COVID-19需要重症监护病房(ICU)的患者的管理,同时重点介绍了目前在COVID-19诱导的ARDS患者的临床试验中评估的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pneumonia
Pneumonia RESPIRATORY SYSTEM-
自引率
1.50%
发文量
7
审稿时长
11 weeks
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信